A panelist discusses how diagnosing and assessing atopic dermatitis across diverse skin types in primary care requires visual familiarity, patient-reported outcomes like itch severity, and practical tools such as body surface area and Investigator’s Global Assessment, emphasizing that effective management depends on combining clinical observation with patient experience.
A panelist discusses how recognizing the diverse presentations and patient demographics of atopic dermatitis—especially adult-onset cases and common mimics like scabies—is essential for accurate diagnosis and management in primary care, with an emphasis on clinical assessment over biopsy and the importance of cultural competence in dermatologic evaluation.
A panelist discusses how a fresh approach to atopic dermatitis management in primary care emphasizes early recognition, appropriate use of new topical therapies, and collaboration with dermatologists to address the disease’s diverse presentations and chronic course.
Panelists discuss how choosing topical treatments requires individualized therapy considering factors such as affected body areas, disease severity, patient age, formulation preferences, and insurance coverage.
Panelists discuss how roflumilast demonstrated good efficacy with 56% to 57% of patients achieving an Investigator’s Global Assessment (IGA) score of 0 or 1 after long-term use, making it effective for maintenance therapy with good tolerability.
Panelists discuss how newer nonsteroidal topical treatments like phosphodiesterase-4 inhibitors (crisaborole and roflumilast), JAK inhibitors (ruxolitinib), and aryl hydrocarbon receptor agonists (tapinarof) are expanding options for atopic dermatitis treatment.
Panelists discuss how long-term use of topical steroids is prevalent with 50% of patients using them 15 to 30 days per month, leading to concerns about adverse effects, including topical steroid withdrawal syndrome.
Panelists discuss how even mild atopic dermatitis can significantly impact quality of life, with 11% of patients with mild symptoms reporting moderate to large impact on their daily functioning.
Panelists discuss how topical steroids should be used intermittently with scheduled breaks to prevent adverse effects like skin atrophy, striae, and telangiectasias.
Panelists discuss how various assessment tools like the IGA, EASI score, and BSA are used to determine the severity of atopic dermatitis and document findings for insurance purposes.
Panelists discuss how atopic dermatitis (AD) affects approximately 7% of adults, has increased by 3% to 5% over the last 5 years, and impacts different body regions depending on age groups.
Panelists discuss how atopic dermatitis presents with red, scaly, itchy, dry, and inflamed skin and is commonly diagnosed in childhood, although it can occur at any age, with frequent flares and comorbid conditions like asthma and allergies.
A panelist discusses how contemporary therapeutic approaches enable successful management of atopic dermatitis through examination of real-world patient cases that demonstrate effective disease control strategies using the latest treatment options.
A panelist discusses how topical treatments for atopic dermatitis can be strategically selected and applied across the lifespan, with considerations for age-specific needs from infancy through adulthood.
A panelist discusses how effective coordination between primary care providers and dermatologists creates a complementary care model that optimizes atopic dermatitis management through shared decision-making, clear communication pathways, and defined roles for each specialty.
A panelist discusses how treatment selection for atopic dermatitis is influenced by multiple considerations including disease severity, patient age, affected body regions, comorbidities, previous treatment responses, and patient preferences.
A panelist discusses how topical JAK inhibitors and AhR agonists represent emerging therapeutic approaches for atopic dermatitis that target specific inflammatory pathways to provide effective symptom relief with distinct mechanisms of action.
A panelist discusses how topical PDE4 inhibitors provide an effective, non-steroidal treatment option for atopic dermatitis by reducing inflammation and improving symptoms with a favorable safety profile.
A panelist discusses how clinicians can select optimal topical treatments for atopic dermatitis by carefully weighing efficacy against potential side effects to create personalized management plans for patients.
A panelist discusses how primary care practitioners can implement efficient diagnostic protocols and treatment pathways to better manage atopic dermatitis patients within the constraints of busy clinical settings.
A panelist discusses how healthcare providers can effectively identify and manage atopic dermatitis flares across different age groups, highlighting the unique challenges and treatment approaches for both pediatric and adult populations.
Panelists discuss how providers should actively screen for vasomotor symptoms (VMS), especially given the lengthy wait times to see specialists, emphasizing that education for both patients and health care providers is essential for timely intervention and effective management.
Panelists discuss how there is no change in therapeutic indication based on this particular finding, though it may serve as a beneficial side effect for patients struggling with sleep difficulties.
Panelists discuss how long-term safety data for fezolinetant and elinzanetant remain unavailable, though short-term results show very positive outcomes with significantly higher efficacy than previous treatment options.
